Pharmacogenetics of β2-agonist drugs in asthma

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 247-258

  Taylor, D Robin ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

2 agonist; Adrenoceptor; Genotype; Haplotype; Polymorphism

Indexed keywords

AMINO ACID; ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FENOTEROL; GLYCINE; LONG ACTING DRUG; METHACHOLINE; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ASIAN; ASTHMA; BETA 2 ADRENERGIC RECEPTOR GENE; BRONCHODILATATION; CARBOXY TERMINAL SEQUENCE; CAUCASIAN; CHROMOSOME; CLINICAL TRIAL; DEMOGRAPHY; DISEASE EXACERBATION; DNA FLANKING REGION; DNA POLYMORPHISM; DOWN REGULATION; ETHNOLOGY; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; LUNG FUNCTION; OPEN READING FRAME; PEAK EXPIRATORY FLOW; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG POTENTIATION; GENETICS;

ADRENERGIC BETA-AGONISTS; ASTHMA; HUMANS; PHARMACOGENETICS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33751331134     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:247     Document Type: Review

References (54)

1. Szentivanyi, A. and Omaha, N. (1968), The beta-adrenergic theory of the atopic abnormality in bronchial asthma. J. Allergy 42, 203-232.
2. Barnes, P. J., Chung, K. F., and Page, C. P. (1998), Inflammatory mediators of asthma: an update. Pharmacol. Rev. 50, 515-596.
3. Shore, S. A., Laporte, J., Hall, I. P., Hardy, E., and Panettieri, R. A. Jr. (1997), Effect of IL-1 beta on responses of cultured human airway smooth muscle cells to bronchodilator agonists. Am. J. Respir. Cell Mol. Biol. 16, 702-712.
4. Shore, S. A. (2002), Cytokine regulation of beta-adrenergic responses in airway smooth muscle. J. Allergy Clin. Immunol. 110, S255-S260.
5. (1942), Osler's Principles and Practice of Medicine. D Appleton Century Company, London UK.
6. Reisman, R. E. (1970), Asthma induced by adrenergic aerosols. J. Allergy 46, 162-177.
7. Eisenstadt, W. S. (1969), Some observations on a new syndrome-respiratory medicamentosa. Ann. Allergy 27, 188-190.
8. 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 11, 259-283.
9. Sears, M. R., Taylor, D. R., Print, C. G., et al. (1990), Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336, 1391-1396.
10. Crane, J., Pearce, N., Flatt, A., et al. (1989), Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1, 917-922.
11. Spitzer, W. O., Suissa, S., Ernst, P., et al. (1992), The use of beta-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 326, 501-506.
12. Reihsaus, E., Innis, M., MacIntyre, N., and Liggett, S. B. (1993), Mutations in the gene encoding for the beta2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8, 334-339.
13. Small, K. M., McGraw, D. W., and Liggett, S. B. (2003), Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411.
14. Schofield, P. R., Rhee, L. M., and Peralta, E. G. (1987), Primary structure of the human beta-adrenergic receptor gene. Nucleic Acids Res. 15, 3636.
15. 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 84, 46-50.
16. 2-adrenergic receptor and their putative promoter regions. J. Biol. Chem. 262, 7321-7327.
17. 2 adrenergic receptor mRNA inhibits receptor synthesis. J. Biol. Chem. 269, 4497-4505.
18. 2-adrenergic receptor regulate receptor expression. J. Clin. Invest. 102, 1927-1932.
19. 2 adrenergic receptor gene. Br. J. Pharmacol. 126, 841-844.
20. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97, 10,483-10,388.
21. Marsh, D. G., Neely, J. D., Breazeale, D. R., et al. (1994), Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 264, 1152-1156.
22. Doull, I. J., Lawrence, S., Watson, M., et al. (1996), Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med. 153, 1280-1284.
23. 2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 156, S156-S162.
24. 2-adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 9, 511-516.
25. Choudhry, S., Ung, N., Avila, P. C., et al. (2005), Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171, 563-570.
26. 2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. 172, 700-703.
27. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry, 33, 9414-9419.
28. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25-33.
29. 2-adrenoceptor on desensitization in human lung mast cells. Pharmacogenetics 10, 153-162.
30. 2-adrenergic receptor gene and desensitization in human airway smooth muscle. Am. J. Respir. Crit. Care Med. 162, 2117-2124.
31. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268, 23,116-23,121.
32. 2-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur. J. Pharmacol. 421, 141-147.
33. McGraw, D. W. and Liggett, S. B. (1999), Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor. Clin. Exp. Allergy 29 (Suppl 4), 43-45.
34. 2-adrenoceptors in asthmatic patients. Chest 115, 324-328.
35. 2-adrenergic receptor genotype-related changes in cAMP levels in peripheral blood mononuclear cells after multiple-dose oral procaterol. Pharm. Res. 18, 1651-1654.
36. 2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 57, 61-66.
37. 2-adrenergic receptor structure. Pulm. Pharmacol. 8, 1-10.
38. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162, 75-80.
39. Israel, E., Chinchilli, V. M., Ford, J. G., et al. (2004), Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364, 1505-1512.
40. 2 adrenoceptor polymorphism. Thorax 55, 762-767.
41. 2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33, 1425-1430.
42. 2-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36, 371-375.
43. Hoit, B. D., Suresh, D. P., Craft, L., Walsh, R. A., and Liggett, S. B. (2000), beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am. Heart J. 139, 537-542.
44. 2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035.
45. 2-adrenoreceptors on haemodynamic responses to adrenaline. Clin. Sci. (Lond.) 104, 509-520.
46. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100, 3184-3188.
47. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 65, 519-525.
48. 2-agonist therapy in asthma. Eur. Respir. J. 11, 589-593.
49. Lemanske, R. F. Jr., Sorkness, C. A., Mauger, E. A., et al. (2001), Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285, 2594-2603.
50. Lazarus, S. C., Boushey, H. A., Fahy, J. V., et al. (2001), Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285, 2583-2593.
51. Wechsler, M. E., Lehman, E., Lazarus, S. C., et al. (2006), Beta-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 173, 519-526.
52. Tattersfield, A. E. and Harrison, T. W. (2006), Beta-adrenoceptor polymorphisms: focus moves to long-acting beta-agonists. Am. J. Respir. Crit. Care Med. 173, 473,474.
53. Tan, S., Hall, I. P., Dewar, J., Dow, E., and Lipworth, B. (1997), Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350, 995-999.
54. 2-agonist therapy. Clin. Sci. (Lond.) 96, 253-259.